| Article ID | Journal | Published Year | Pages | File Type | 
|---|---|---|---|---|
| 10914832 | Molecular Oncology | 2015 | 10 Pages | 
Abstract
												PhosphoChk1 and H2AX are useful biomarkers for ATR inhibition using a variety of immuno-detection methods, but timing may be critical. Importantly, ATR activity is detectable in non-cycling PBMCs allowing them to be used as a surrogate tissue for biomarker measurement. In PBMCs from whole blood treated with 4NQO phosphoH2AX was the most useful biomarker of ATR activity and a clinically viable pharmacodynamic assay for ATR inhibitors has been developed.
											Related Topics
												
													Life Sciences
													Biochemistry, Genetics and Molecular Biology
													Cancer Research
												
											Authors
												Tao Chen, Fiona K. Middleton, Susanna Falcon, Philip M. Reaper, John R. Pollard, Nicola J. Curtin, 
											